<DOC>
	<DOC>NCT01770223</DOC>
	<brief_summary>This study is being done to find out if participants with insulin resistance and hepatitis C virus genotype 1 (HCV GT1) infections who failed dual therapy with peginterferon alfa (PegIFN) + ribavirin (RBV) will benefit from the addition of boceprevir to PegIFN + RBV (triple therapy).</brief_summary>
	<brief_title>A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Inclusion criteria: Quantifiable serum hepatitis C virusribonucleic acid (HCVRNA) Hepatitis C virus genotype 1 Homeostasis Model of Assessment Insulin Resistance (HOMA IR) &gt; 2.5 in two determinations made 4 weeks apart (the first HOMA evaluation is able to be made 3 weeks before screening visit) Previous failure to achieve SVR with PegIFN plus ribavirin given for a minimum of 12 weeks without dose reduction below 80% of the adequate doses of the two drugs No response, partial response, or relapse after previous therapy Compensated liver disease with or without histologic or noninvasive evidence of liver cirrhosis If heterosexually active, a female participant of childbearing potential and a nonvasectomized male participant who has a female partner of childbearing potential must agree to use 2 effective contraceptives until 6 months after therapy has ended (7 months for male subject) Exclusion criteria: Coinfection with HCV genotypes other than HCVGT1 Evidence of decompensated liver disease History of ascites, hepatic encephalopathy or of bleeding varices or severe portal hypertension History or signs or symptoms or evidence of hepatocellular carcinoma (HCC) History of organ transplant Coinfection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Severe psychiatric disease Inadequately controlled thyroid function Other important comorbidities (cardiovascular diseases, Type 1 diabetes or inadequately controlled type 2 diabetes, malignancies , etc) Substances abuse Alcohol intake &gt;20 grams/day for females and &gt;30 grams/day for males History of severe adverse events during previous treatment with PegIFN plus ribavirin including discontinuation of therapy for severe anemia or hematologic toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>